Dan Edelstein

Dan Edelstein is President and Chief Executive Officer at Haystack Oncology. Dan has over 15 years of liquid biopsy clinical development and commercialization experience. He was previously part of the team at Johns Hopkins that pioneered the use of circulating tumor DNA (ctDNA) to detect and track the progression of cancer. In 2011, while at Inostics, he led the development of the world’s first CLIA laboratory for ctDNA analyses, delivering the first commercially available liquid biopsy assay for clinical practice and prospective clinical trials. Dan was previously the chief commercial officer at Sysmex Inostics where he developed a deep understanding of the clinical requirements for liquid biopsy product development, market access strategies, clinical utility evidence generation and biopharma partnerships.